Dehydroascorbic acid for the treatment of acute ischemic stroke

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Acute ischemic stroke causes significant brain damage due to oxidative stress and nutrient depletion.
• Ascorbic acid (AA) is a crucial brain protector, but its levels rapidly decline during ischemic events.
• Dehydroascorbic acid (DHAA) readily crosses the blood-brain barrier and converts to AA, offering potential therapeutic benefits.

Purpose of the Study:

• To investigate the efficacy of intravenous DHAA in reducing infarct volume and improving functional recovery in animal models of acute ischemic stroke.
• To explore the mechanistic rationale and safety profile of DHAA as a potential treatment for human stroke.

Main Methods:

• Administration of intravenous DHAA in rodent models of experimental stroke.
• Assessment of infarct volume, functional recovery, and pharmacokinetic properties of DHAA.
• Evaluation of DHAA's conversion to AA and its downstream protective effects in brain tissue.

Main Results:

• Intravenous DHAA administration significantly minimized infarct volume and facilitated functional recovery in animal stroke models.
• DHAA demonstrated efficacy even when administered up to three hours post-infarct.
• Mechanistic studies revealed DHAA's ability to replenish AA levels, support antioxidant systems, and protect against oxidative damage.

Conclusions:

• DHAA shows significant neuroprotective potential in preclinical models of acute ischemic stroke.
• The conversion of DHAA to AA provides a robust therapeutic strategy by restoring antioxidant capacity and supporting neuronal function.
• DHAA is a promising candidate for human clinical trials, with potential application in pre-hospital stroke management.